Latham & Watkins has advised GSK on a strategic research collaboration and option agreement with Engitix, a biotechnology company pioneering extracellular matrix (ECM)-driven drug discovery, to identify and validate novel therapeutic targets driving liver fibrosis regression.
The Latham team was led by London partner Lydia Torne, with associate Luke Nauth.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.